首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1829292

2025年核子醫學診斷全球市場報告

Nuclear Medicine Diagnostics Global Market Report 2025

出版日期: 2025年09月11日 | 出版商:

The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄

近年來，核子醫學診斷市場規模迅速擴張，從2024年的71.6億美元成長到2025年的78.8億美元，複合年成長率達10.2%。這段歷史時期的成長可歸因於醫學影像技術的進步、慢性病盛行率的上升、人口老化趨勢、腫瘤學臨床應用以及診斷精度和準確度的提高。

預計未來幾年核醫診斷市場將快速成長，到2029年將達到123.8億美元，年複合成長率（CAGR）為11.9%。預測期內的成長歸因於神經病學應用的不斷擴展、與其他顯像模式的整合、精準醫療方法、對治療診斷學日益成長的需求以及全球根除疾病的努力。預測期內的主要趨勢包括向小型分散式放射性藥物藥房的轉變、核醫學在神經病學中的應用、放射組學和定量成像分析、研發合作以及對輻射安全和劑量測定的日益關注。

核子醫學利用放射性物質注入體內來診斷疾病，或在治療過程中選擇性地靶向並切除患病或受損的器官或組織。該領域涵蓋將放射性藥物用於研究、治療和診斷目的。診斷性核子醫學使用放射性示蹤劑來觀察和/或測量特定器官的整體或局部功能，為醫學診斷和治療計劃提供寶貴的見解。

核子醫學診斷的主要類別包括SPECT放射性藥物和PET放射性藥物。 SPECT放射性藥物（單光子發射電腦斷層掃描）與核子醫學領域使用的伽馬射線斷層掃描技術相關。這些方法可應用於心臟病學、甲狀腺學、神經病學和腫瘤學等多個醫學領域。這些診斷技術的最終用戶包括醫院、診斷中心和研究機構。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要醫療設備重新認證，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供您在核醫學診斷行業取得成功所需的數據，涵蓋核醫學診斷市場統計數據，例如全球市場規模、區域佔有率、核醫學診斷市場佔有率的競爭對手、詳細的核醫學診斷細分市場、市場趨勢和商業機會。這份核子醫學診斷市場研究報告透過對產業現狀和未來趨勢的詳細分析，全面展望了您所需的一切。

未來五年的預測成長率為11.9%，較我們先前對該市場的預測略有下降0.2%。這一下降主要源自於美國與其他國家之間關稅的影響。此影響可能直接影響美國，包括對比利時鍺-68/鎵-68發生器的關稅上調、聚對苯二甲酸乙二醇酯(PET)放射性藥物成本上升，以及可能限制獲得晚期癌症分期方法。此外，互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響也將對美國產生更廣泛的影響。

由於對這種診斷技術的需求不斷成長，核醫學診斷市場預計將成長。核子醫學利用體內的放射性物質來診斷疾病，並在治療過程中瞄準和切除患病或受損的器官和組織。核子醫學診斷的主要用途是放射治療和其他挽救生命的治療。由於此類診斷具有許多好處，包括準確的結果和改進的治療決策能力，對此類診斷的需求正在增加。根據倡導核能發電的英國國際組織世界核能協會 2022 年 4 月報道，核子醫學治療的數量每年將超過 4,000 萬次，放射性同位素的需求每年以高達 5% 的速度成長。值得注意的是，全球 90% 以上的涉及放射性同位素的醫療程序是在全球 10,000 多家醫院進行的。需求的激增凸顯了核醫學診斷的關鍵作用，並有助於核醫診斷市場的預期成長。

預計癌症發生率的上升將在未來幾年推動核醫學診斷市場的成長。癌症是指一系列以異常細胞不受控制地生長和擴散為特徵的疾病，導致腫瘤的形成。核子醫學診斷利用可被特殊相機識別的放射性物質生成器官和組織內部結構和功能的詳細影像，在各種癌症的檢測、分期和監測中發揮關鍵作用。例如，2023年1月，美國政府間組織國家生物技術資訊中心報告稱，當年美國新增癌症病例數為1,958,310例，癌症相關死亡人數為609,820例。因此，癌症患者數量的增加正在刺激核醫診斷市場的擴張。

核子醫學診斷市場的主要企業正策略性地專注於採用先進的解決方案，尤其是先進的醫療技術，以建立競爭優勢。先進的醫療技術是指醫療領域的尖端創新，旨在改善患者的治療效果、提高護理水平並促進整體健康。馬來西亞醫療保健服務提供者鷹閣醫院就是一個例子。 2023 年 8 月，該醫院引入了核子醫學治療室，展示了對先進醫療技術的承諾。該專科病房配備了尖端技術並配備了熟練的專業人員，旨在透過核子醫學掃描術診斷技術促進疾病的早期發現、診斷和治療。領先公司的此類努力凸顯了該行業致力於技術進步和提高核醫學診斷市場的醫療能力。

核子醫學診斷市場包括腎臟掃描、骨骼掃描、鎵掃描、心臟掃描、腦部掃描和乳房掃描的銷售。該市場的價值是“出廠價”，即商品製造商或創造者出售給其他營業單位（包括下游製造商、經銷商、分銷商和零售商）或直接出售給最終客戶的商品價值。該市場中的商品價值還包括商品創造者出售的任何相關服務。

全球核子醫學診斷：PESTEL分析（政治、社會、科技、環境、法律因素、促進因素與限制因素）
最終用途產業分析
全球核子醫學診斷市場：成長率分析
全球核子醫學診斷市場表現：規模與成長，2019-2024
全球核子醫學診斷市場預測：規模與成長，2024-2029年，2034年
全球核子醫學診斷：總目標市場（TAM）

第6章市場細分

全球核子醫學診斷市場：依類型、績效與預測，2019-2024 年、2024-2029 年、2034 年
SPECT放射性藥物
PET放射性藥物
全球核子醫學診斷市場：應用、績效及預測（2019-2024年、2024-2029年、2034年）
心臟病學
甲狀腺
神經病學
腫瘤學
其他用途
全球核子醫學診斷市場：按最終用戶、績效和預測，2019-2024 年、2024-2029 年、2034 年
醫院和診斷中心
研究機構
全球核子醫學診斷市場：依 SPECT 放射性藥物類型細分、績效及預測（2019-2024 年、2024-2029 年、2034 年）
Technetium-99m放射性藥物
碘-123放射性藥物
鉈-201放射性藥物
其他 SPECT 放射性藥物
全球核子醫學診斷市場：PET放射性藥物細分（按類型）、績效及預測，2019-2024年、2024-2029年、2034年
氟-18放射性藥物
碳-11放射性藥物
鎵-68基放射性藥物
其他PET放射性藥物

第7章區域和國家分析

全球核子醫學診斷市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
全球核子醫學診斷市場：依國家、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章亞太市場

第9章：中國市場

第10章印度市場

第11章日本市場

第12章：澳洲市場

第13章印尼市場

第14章韓國市場

第15章西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章東歐市場

第22章俄羅斯市場

第23章北美市場

第24章美國市場

第25章：加拿大市場

第26章南美洲市場

第27章：巴西市場

第28章中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

核子醫學診斷市場：競爭格局
核子醫學診斷市場：公司簡介
- Siemens AG Overview, Products and Services, Strategy and Financial Analysis
- Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- GE Healthcare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
- Perkin Elmer Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

Mallinckrodt Pharmaceuticals
Bracco Diagnostics Inc.
Lantheus Holdings Inc.
IBA Radiopharma Solutions
Curium SAS
Cardinal Health Inc.
Eckert & Ziegler Strahlen-und Medizintechnik AG
Advanced Accelerator Applications
Telix Pharmaceuticals Limited
Nordion（Canada）Inc.
NorthStar Medical Technologies LLC
SHINE Medical Technologies LLC
Navidea Biopharmaceuticals Inc.
Cyclopharm Limited
Isologic Innovative Radiopharmaceuticals

第 32 章全球市場競爭基準化分析與儀表板

第33章重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

2029年核子醫學診斷市場：提供新機會的國家
2029年核子醫學診斷市場：細分領域帶來新機會
2029年核子醫學診斷市場：成長策略
- 基於市場趨勢的策略
- 競爭對手策略

第36章附錄

簡介目錄

Product Code: r26800u

Nuclear medicine employs radioactive substances administered internally to diagnose illnesses or selectively target and eliminate diseased or damaged organs and tissues during treatment. This field encompasses the utilization of radioactive drugs for research, therapeutic, and diagnostic objectives. In diagnostic nuclear medicine, radioactive tracers are employed to visualize and/or measure the overall or localized function of specific organs, providing valuable insights for medical diagnosis and treatment planning.

The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $7.16 billion in 2024 to $7.88 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to advancements in medical imaging, increasing prevalence of chronic diseases, aging population trends, clinical applications in oncology, diagnostic accuracy and precision.

The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $12.38 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to expanding applications in neurology, integration with other imaging modalities, precision medicine approaches, rising demand for theranostics, global efforts in disease eradication. Major trends in the forecast period include shift towards small-scale, decentralized radiopharmacy, application of nuclear medicine in neurology, radiomics and quantitative imaging analysis, collaborations for research and development, emphasis on radiation safety and dosimetry.

The forecast of 11.9% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through increased duties on germanium-68/gallium-68 generators from Belgium, raising costs for polyethylene terephthalate (PET) radiopharmaceuticals and potentially limiting access to advanced cancer staging procedures.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth of the nuclear medicine diagnostics market is driven by a rising demand for these diagnostic techniques. Nuclear medicine utilizes radioactive substances within the body for diagnosing illnesses and for targeted removal of diseased or damaged organs and tissues during treatment. The applications of nuclear medicine diagnostics are predominantly in radiation and other life-saving treatments. The increasing demand for these diagnostics is attributed to their advantages, including accurate results and enhanced treatment decision-making capabilities. As reported in April 2022 by the World Nuclear Association, a UK-based international organization advocating for nuclear power, the annual number of nuclear medicine treatments surpasses 40 million, with the demand for radioisotopes witnessing a yearly growth rate of up to 5%. Notably, over 90% of procedures involving radioisotopes in medicine are conducted in more than 10,000 hospitals worldwide. This surge in demand underscores the pivotal role of nuclear medicine diagnostics, contributing to the anticipated growth of the nuclear medicine diagnostics market.

The increasing incidence of cancer is anticipated to drive the growth of the nuclear medicine diagnostics market in the coming years. Cancer refers to a collection of diseases characterized by the uncontrolled proliferation and spread of abnormal cells, which can lead to the formation of tumors. Nuclear medicine diagnostics plays a crucial role in detecting, staging, and monitoring various cancer types by using radioactive substances that can be identified by specialized cameras, producing detailed images of the internal structures and functions of organs and tissues. For example, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, reported that there were 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States that year. Thus, the rising number of cancer cases is fueling the expansion of the nuclear medicine diagnostics market.

Prominent companies in the nuclear medicine diagnostics market are strategically focusing on the introduction of advanced solutions, particularly advanced medical technologies, to establish a competitive advantage. Advanced medical technologies represent cutting-edge innovations within the medical field, aimed at improving patient outcomes, elevating the standard of care, and fostering overall health improvement. An illustrative example is Gleneagles Hospital, a Malaysia-based company providing medical and healthcare services. In August 2023, the hospital introduced a Nuclear Medicine Unit, showcasing its commitment to advanced medical technologies. This specialized unit, equipped with state-of-the-art technology and staffed by highly skilled professionals, is designed to facilitate early detection, diagnosis, and treatment of diseases through nuclear medicine imaging techniques. Such initiatives by major companies underscore the industry's dedication to advancing technology and enhancing medical capabilities within the nuclear medicine diagnostics market.

Major companies in the nuclear medicine diagnostics market are actively pursuing strategic partnerships as a key approach to securing a competitive edge. Strategic partnerships involve collaborative efforts between two or more entities with the goal of achieving mutually advantageous objectives by combining resources and expertise. A noteworthy example occurred in June 2023, where RLS Inc., a US-based nuclear medicine provider, entered into a strategic partnership with SOFIE, a US-based molecular imaging company. Through this collaboration, RLS Inc. aims to enhance the distribution of nuclear medicine doses to patients, hospitals, teaching institutions, and doctors, thereby improving the overall continuum of care for patients. This strategic partnership will streamline patient dose preparation, capitalizing on the accredited radiopharmacy network and expertise of both entities involved. Such initiatives underscore the industry's commitment to fostering collaboration and leveraging collective strengths to drive advancements in the nuclear medicine diagnostics market.

In January 2022, Eckert & Ziegler, a Germany-based provider of isotope technology for medical, scientific, and industrial applications, successfully acquired Tecnonuclear SA for an undisclosed sum. This strategic acquisition positions Eckert & Ziegler to broaden its footprint and enhance essential healthcare services in Brazil and across South America. Tecnonuclear SA, an Argentina-based specialist in nuclear medicine, brings valuable expertise and resources to strengthen Eckert & Ziegler's presence in the region, aligning with the company's commitment to advancing isotope technology for medical applications.

Major companies operating in the nuclear medicine diagnostics market include Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Cardinal Health Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Global Medical Solutions LLC, Theragnostics Ltd., EczacIbasI-Monrol Nuclear Products Co.

North America was the largest region in the nuclear medicine diagnostics market in 2024. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: SPECT Radiopharmaceuticals; PET Radiopharmaceuticals
2) By Application: Cardiology; Thyroid; Neurology; Oncology; Other Applications
3) By End-User: Hospitals And Diagnostic Centers; Research Institutes
Subsegments:
1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals; Iodine-123-Based Radiopharmaceuticals; Thallium-201-Based Radiopharmaceuticals; Other SPECT Radiopharmaceuticals
2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals; Carbon-11-Based Radiopharmaceuticals; Gallium-68-Based Radiopharmaceuticals; Other PET Radiopharmaceuticals
Companies Mentioned: Siemens AG; Bayer Aktiengesellschaft; Novartis AG; GE Healthcare Technologies Inc.; Perkin Elmer Inc.; Mallinckrodt Pharmaceuticals; Bracco Diagnostics Inc.; Lantheus Holdings Inc.; IBA Radiopharma Solutions; Curium SAS; Cardinal Health Inc.; Eckert & Ziegler Strahlen- und Medizintechnik AG; Advanced Accelerator Applications; Telix Pharmaceuticals Limited; Nordion (Canada) Inc.; NorthStar Medical Technologies LLC; SHINE Medical Technologies LLC; Navidea Biopharmaceuticals Inc.; Cyclopharm Limited; Isologic Innovative Radiopharmaceuticals; Clarity Pharmaceuticals Limited; Actinium Pharmaceuticals Inc.; Jubilant DraxImage Inc.; PharmaLogic Holdings Corp; Institute of Isotopes Co Ltd.; Global Medical Solutions LLC; Theragnostics Ltd.; EczacIbasI-Monrol Nuclear Products Co.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

1. Executive Summary

2. Nuclear Medicine Diagnostics Market Characteristics

3. Nuclear Medicine Diagnostics Market Trends And Strategies

4. Nuclear Medicine Diagnostics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Nuclear Medicine Diagnostics Growth Analysis And Strategic Analysis Framework

5.1. Global Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Nuclear Medicine Diagnostics Market Growth Rate Analysis
5.4. Global Nuclear Medicine Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Nuclear Medicine Diagnostics Total Addressable Market (TAM)

6. Nuclear Medicine Diagnostics Market Segmentation

6.1. Global Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
6.2. Global Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cardiology
Thyroid
Neurology
Oncology
Other Applications
6.3. Global Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Diagnostic Centers
Research Institutes
6.4. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of SPECT Radiopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Technetium-99m-Based Radiopharmaceuticals
Iodine-123-Based Radiopharmaceuticals
Thallium-201-Based Radiopharmaceuticals
Other SPECT Radiopharmaceuticals
6.5. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of PET Radiopharmaceuticals, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fluorine-18-Based Radiopharmaceuticals
Carbon-11-Based Radiopharmaceuticals
Gallium-68-Based Radiopharmaceuticals
Other PET Radiopharmaceuticals

7. Nuclear Medicine Diagnostics Market Regional And Country Analysis

7.1. Global Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nuclear Medicine Diagnostics Market

8.1. Asia-Pacific Nuclear Medicine Diagnostics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nuclear Medicine Diagnostics Market

9.1. China Nuclear Medicine Diagnostics Market Overview
9.2. China Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nuclear Medicine Diagnostics Market

10.1. India Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nuclear Medicine Diagnostics Market

11.1. Japan Nuclear Medicine Diagnostics Market Overview
11.2. Japan Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nuclear Medicine Diagnostics Market

12.1. Australia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nuclear Medicine Diagnostics Market

13.1. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nuclear Medicine Diagnostics Market

14.1. South Korea Nuclear Medicine Diagnostics Market Overview
14.2. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nuclear Medicine Diagnostics Market

15.1. Western Europe Nuclear Medicine Diagnostics Market Overview
15.2. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nuclear Medicine Diagnostics Market

16.1. UK Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nuclear Medicine Diagnostics Market

17.1. Germany Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nuclear Medicine Diagnostics Market

18.1. France Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nuclear Medicine Diagnostics Market

19.1. Italy Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nuclear Medicine Diagnostics Market

20.1. Spain Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nuclear Medicine Diagnostics Market

21.1. Eastern Europe Nuclear Medicine Diagnostics Market Overview
21.2. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nuclear Medicine Diagnostics Market

22.1. Russia Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nuclear Medicine Diagnostics Market

23.1. North America Nuclear Medicine Diagnostics Market Overview
23.2. North America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nuclear Medicine Diagnostics Market

24.1. USA Nuclear Medicine Diagnostics Market Overview
24.2. USA Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nuclear Medicine Diagnostics Market

25.1. Canada Nuclear Medicine Diagnostics Market Overview
25.2. Canada Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nuclear Medicine Diagnostics Market

26.1. South America Nuclear Medicine Diagnostics Market Overview
26.2. South America Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nuclear Medicine Diagnostics Market

27.1. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nuclear Medicine Diagnostics Market

28.1. Middle East Nuclear Medicine Diagnostics Market Overview
28.2. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nuclear Medicine Diagnostics Market

29.1. Africa Nuclear Medicine Diagnostics Market Overview
29.2. Africa Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

30.1. Nuclear Medicine Diagnostics Market Competitive Landscape
30.2. Nuclear Medicine Diagnostics Market Company Profiles
- 30.2.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GE Healthcare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Perkin Elmer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

31.1. Mallinckrodt Pharmaceuticals
31.2. Bracco Diagnostics Inc.
31.3. Lantheus Holdings Inc.
31.4. IBA Radiopharma Solutions
31.5. Curium SAS
31.6. Cardinal Health Inc.
31.7. Eckert & Ziegler Strahlen- und Medizintechnik AG
31.8. Advanced Accelerator Applications
31.9. Telix Pharmaceuticals Limited
31.10. Nordion (Canada) Inc.
31.11. NorthStar Medical Technologies LLC
31.12. SHINE Medical Technologies LLC
31.13. Navidea Biopharmaceuticals Inc.
31.14. Cyclopharm Limited
31.15. Isologic Innovative Radiopharmaceuticals

32. Global Nuclear Medicine Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market

34. Recent Developments In The Nuclear Medicine Diagnostics Market

35. Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies

35.1 Nuclear Medicine Diagnostics Market In 2029 - Countries Offering Most New Opportunities
35.2 Nuclear Medicine Diagnostics Market In 2029 - Segments Offering Most New Opportunities
35.3 Nuclear Medicine Diagnostics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies